Two MD Anderson faculty members honored with highest distinctions from ASCO

March 16, 2016

The American Society of Clinical Oncology (ASCO) will recognize two physician-scientists from The University of Texas MD Anderson Cancer Center with two of its highest distinctions at its annual meeting in Chicago.

Ethan Dmitrovsky, M.D., provost and executive vice president and professor of Thoracic/Head and Neck Medical Oncology and of Cancer Biology, will be honored for his efforts in cancer prevention and control with the 2016 ASCO-American Cancer Society Award and Lecture. Waun Ki Hong, M.D., professor of Thoracic/Head and Neck Medical Oncology and former head of Cancer Medicine, will be honored for the major impact he has had on the field as well as for his long-standing commitment to ASCO with the Special Recognition Award.

"The extraordinary efforts and seminal contributions of these two leading physician-scientists have made an enduring impact in the assault against cancer," said Ronald DePinho, M.D., president of MD Anderson. "These high honors recognize two incredible researchers who have not only transformed cancer medicine but, through their gifted leadership, have made MD Anderson a global leader in cancer research and care."

Research benefits leukemia and lung cancer patients

Dmitrovsky will receive the ASCO-American Cancer Society Award and deliver a lecture on Monday, June 6.

As an MD Anderson leader who also works at the bench and in the clinic, he is grateful for the honor.

"I am humbled and honored to receive this recognition," he said. "It is a privilege to serve the oncology community and our patients whether as an oncologist, physician-researcher, mentor or leader."

Dmitrovsky is being recognized for his groundbreaking work on the mechanisms behind the tumor-suppressing effects of natural synthetic derivatives of vitamin A, known as retinoids.

He and his team helped establish use of all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL), the vital component in combination treatment that leads to complete remission and five-year survival of over 90 percent of patients. APL was frequently fatal prior to this finding. Dmitrovsky and colleagues also developed and patented a genetic test that is often used to diagnose APL and monitor treatment.

Dmitrovsky now focuses on lung cancer, building on his work with APL.

His team has:

New approaches to cancer prevention and treatment

Hong will be presented with the Special Recognition Award at the ASCO President's Dinner on Friday, June 3.

He said he is honored to receive this reward for his research, especially from an organization he helped build.

"I thank the wonderful colleagues and trainees who have been a part of our MD Anderson team," said Hong. "It is vital that we always work collaboratively to advance our knowledge, and never lose sight of our patients who rely on us."

In the early 1980s, Hong conceived and led a series of landmark clinical trials showing that patients with laryngeal cancer fared just as well when treated with chemotherapy and radiation as those who underwent surgery that ultimately resulted in removing the larynx and losing the ability to speak. This new model helped shift treatment toward organ conservation in other cancers, including anal and breast cancer.

He is one of the founders of cancer chemoprevention research and pioneered a new paradigm for cancer - the possibility that it can be prevented or delayed. His studies demonstrating that high-dose retinoic acid can reverse oral premalignant lesions and prevent the development of second primary tumors were the first to prove that chemoprevention can work in humans.

Hong also led the development of personalized molecular targeted therapies for lung cancer. He established the groundbreaking Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) clinical trial for lung cancer, a first-of-its-kind effort to match treatment to tumor characteristics. His most recent project, Profiling of Resistance Patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification (PROSPECT), has identified several molecular targets and pathways in cell lines that predict drug sensitivity and resistance. Clinical application of these findings is underway in developing and testing personalized therapeutic strategies for non-small-cell lung cancer and mesothelioma.
-end-


University of Texas M. D. Anderson Cancer Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.